Sotac Pharmaceuticals Ltd (SOTAC) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sotac Pharmaceuticals Limited is a pharmaceutical manufacturing company in Gujarat, India, specializing in a wide range of pharmaceutical products under loan licensing or contract manufacturing partnerships. The company has a robust portfolio covering therapeutic areas such as anti-diabetics, anti-psychotics, and antibiotics, serving a broad client base in pharmaceutical development and production. In 2022, Sotac Pharmaceuticals expanded strategically by acquiring holdings in SOTAC Healthcare and SOTAC Research, indicating a significant shift towards enhancing its research and healthcare capabilities. The company went public with an IPO in April 2023, raising Rs 33 crore, which will likely support its expansion and operational initiatives. Sotac Pharmaceuticals has been on a growth trajectory since its establishment, now operating as a public limited company, reflecting increasing trust and ambition within the pharmaceutical sector.

Over the past 52 weeks, Sotac Pharmaceuticals Ltd has traded between a low of ₹86.00 and a high of ₹139.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sotac Pharmaceuticals Ltd has a market capitalization of approximately 99.51. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sotac Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 25.19 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 99.51 Cr, Sotac Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sotac Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sotac Pharmaceuticals Ltd is 25.19. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.